Bausch Health Companies Inc Stock Price, News & Analysis

Bausch Health (NYSE/TSX: BHC) announced that XIFAXAN® (rifaximin) 550 mg tablets has been selected by the Centers for Medicare and Medicaid Services (CMS) for the second round of price negotiations under the Inflation Reduction Act. The negotiated pricing will take effect in 2027.

The company plans to engage with CMS to demonstrate XIFAXAN's healthcare system value, highlighting recommendations from The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), which gave XIFAXAN® their highest recommendation (Grade I, A,1) in practice guidelines.

Bausch Health Companies (NYSE/TSX: BHC) has confirmed it is exploring potential sale options for its subsidiary Bausch + Lomb (NYSE/TSX: BLCO) as one of several alternatives to complete their separation. The statement was issued in response to a request from the Canadian Investment Regulatory Organization (CIRO) due to stock volatility concerns related to market rumors.

The company emphasized that while the Board of Directors has authorized management to explore a potential sale, no decision has been made to proceed with any particular transaction, and there is no guarantee that the process will result in a deal. The company stated it will not provide additional details until further disclosure becomes appropriate or necessary.

Bausch Health (NYSE/TSX:BHC) and its GI business, Salix Pharmaceuticals, along with major health organizations, are commemorating the second annual Opioid-Induced Constipation (OIC) Awareness Day on December 5, 2024. The initiative aims to raise awareness about OIC, a common side effect of opioid treatment.

According to statistics, approximately 21% of U.S. adults experienced chronic pain in 2021, with 22% of chronic pain patients receiving opioid prescriptions in 2019. To support the cause, Salix has updated the OICAwarenessDay.com website with resources for healthcare providers, patients, and caregivers. The campaign includes partnerships with influencers, a content program with Chronicon, and social media engagement using hashtags #OICAwarenessDay and #vOICesOfOIC.

Bausch Health (NYSE/TSX:BHC) has appointed Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. Dr. Sadeh brings over 20 years of experience in clinical research and drug development, most recently at Bristol-Meyers Squibb where he served as Senior Vice President and Global Programs Head. His track record includes multiple drug approvals in dermatology and gastroenterology. Dr. Sadeh holds a master's degree from Harvard Medical School and a medical degree from Mount Sinai School of Medicine, with previous experience at Sanofi, Astra-Zeneca, and Schering-Plough.

Bausch Health and Salix Pharmaceuticals announced the presentation of their RED-C Phase 3 clinical trial program at AASLD. The study evaluates a next-generation soluble solid dispersion (SSD) immediate-release rifaximin product designed to delay the onset of first overt hepatic encephalopathy (OHE) hospitalization in cirrhosis patients. The program consists of two global Phase 3 trials involving over 1,000 patients across 398 study sites in 17 countries. Patient enrollment is complete, with efficacy and safety results pending. The therapeutic aims to enhance gastrointestinal luminal solubility while limiting systemic exposure, addressing an unmet medical need as there are currently no approved medications for primary prophylaxis of OHE in cirrhosis.

Bausch Health Canada announced positive reimbursement recommendations from Canada's Drug Agency (CDA) and Quebec's INESSS for PrCABTREO, their triple-combination topical treatment for acne vulgaris. The gel, containing clindamycin phosphate, adapalene, and benzoyl peroxide, is approved for patients 12 years and older. As the first and only triple-combination topical acne treatment approved by Health Canada, CABTREO combines three mechanisms of action. The company will now work with the pan-Canadian Pharmaceutical Alliance to finalize reimbursement terms for Canada's public drug plans. The prescription therapy is currently available through pharmacies across Canada.

Bausch Health (BHC) reported strong Q3 2024 results with consolidated revenues of $2.51 billion, up 12% year-over-year, marking the sixth consecutive quarter of growth. The company achieved organic revenue growth of 9%, with all segments showing positive performance. Despite a GAAP net loss of $85 million, Adjusted EBITDA increased 10% to $909 million. Notable segment performances included Bausch + Lomb (+19%), Solta Medical (+35%), and Salix (+5%). Based on these results, BHC raised its full-year 2024 guidance, projecting revenues between $9.500-$9.675 billion and Adjusted EBITDA of $3.275-$3.375 billion.

Bausch Health announced upcoming presentations at the American College of Gastroenterology 2024 Annual Scientific Meeting, featuring key analyses of Xifaxan and Plenvu. The main highlight is a Presidential Plenary presentation comparing Xifaxan monotherapy to lactulose monotherapy in reducing overt hepatic encephalopathy (OHE) recurrence and mortality. Additional research includes data on Xifaxan's impact on OHE rehospitalizations in commercial and Medicare patients, and Plenvu's efficacy as a bowel preparation medication in patients with comorbid conditions or taking medications affecting bowel prep quality.

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) has announced that it will release its third quarter 2024 financial results after market close on Wednesday, October 30, 2024. The company will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update.

All materials related to the financial results will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call. Interested parties can access the webcast through the company's website. A replay of the conference call will also be available on the investor relations website for those unable to attend the live event.

To participate in the live Q&A session, individuals must register using a provided link to receive confirmation and further details via email.